CA2626774A1 - Class iii slrp for the treatment of cancer - Google Patents

Class iii slrp for the treatment of cancer Download PDF

Info

Publication number
CA2626774A1
CA2626774A1 CA002626774A CA2626774A CA2626774A1 CA 2626774 A1 CA2626774 A1 CA 2626774A1 CA 002626774 A CA002626774 A CA 002626774A CA 2626774 A CA2626774 A CA 2626774A CA 2626774 A1 CA2626774 A1 CA 2626774A1
Authority
CA
Canada
Prior art keywords
cancer
class iii
use according
agent
opticin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002626774A
Other languages
English (en)
French (fr)
Inventor
Paul N. Bishop
Rachel L. Cowen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Manchester
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2626774A1 publication Critical patent/CA2626774A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002626774A 2004-10-20 2005-10-13 Class iii slrp for the treatment of cancer Abandoned CA2626774A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0423273.2 2004-10-20
GBGB0423273.2A GB0423273D0 (en) 2004-10-20 2004-10-20 Treatment of cancer
PCT/GB2005/003940 WO2006043031A2 (en) 2004-10-20 2005-10-13 Class iii slrp for the treatment of cancer

Publications (1)

Publication Number Publication Date
CA2626774A1 true CA2626774A1 (en) 2006-04-27

Family

ID=33484868

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002626774A Abandoned CA2626774A1 (en) 2004-10-20 2005-10-13 Class iii slrp for the treatment of cancer

Country Status (6)

Country Link
US (1) US20080096793A1 (enExample)
EP (1) EP1809314A2 (enExample)
JP (1) JP2008517045A (enExample)
CA (1) CA2626774A1 (enExample)
GB (1) GB0423273D0 (enExample)
WO (1) WO2006043031A2 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004105784A1 (en) * 2003-05-29 2004-12-09 The University Of Manchester Class iii slrp agonists for the reduction of blood vessel formation
CN102549436A (zh) 2009-07-27 2012-07-04 霍夫曼-拉罗奇有限公司 mimecan在评价心力衰竭中的用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5827702A (en) * 1994-10-31 1998-10-27 Genentech, Inc. Ocular gene therapy
DE4445630A1 (de) * 1994-12-21 1996-06-27 Forssmann Wolf Georg Humane zirkulierende Peptidfragmente 20-92 und 23-74 des Precursor des Osteoinduktiven Faktors kurz: OIF-20-92 und OIF 23-74
AU5593398A (en) * 1996-12-05 1998-06-29 Alcon Laboratories, Inc. The use of inhibitors of tgf-beta's functions to ameliorate ocular pathology
WO2000068264A2 (en) * 1999-05-10 2000-11-16 The Texas A & M University System A peptide inhibitor of fibrinogen blood clotting
US7304137B2 (en) * 2001-12-13 2007-12-04 The Texas A & M University System Nucleotide and amino acid sequences of asporins
WO2004105784A1 (en) * 2003-05-29 2004-12-09 The University Of Manchester Class iii slrp agonists for the reduction of blood vessel formation

Also Published As

Publication number Publication date
JP2008517045A (ja) 2008-05-22
WO2006043031A2 (en) 2006-04-27
WO2006043031A3 (en) 2006-07-06
US20080096793A1 (en) 2008-04-24
EP1809314A2 (en) 2007-07-25
GB0423273D0 (en) 2004-11-24

Similar Documents

Publication Publication Date Title
EP2807180B1 (en) Peptide agents for cancer therapy
KR102694658B1 (ko) 혈관 신생 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물
JP5650639B2 (ja) 腫瘍疾患の治療
EP3013353B1 (en) Cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of cystitis
AU2013202137A1 (en) Peptide agents for cancer therapy
CN107108715A (zh) 胰高血糖素和glp‑1受体的共激动剂
WO2011044374A1 (en) Capcna peptide therapeutics for cancer
US7910567B2 (en) Opticin nucleic acid administration reduces blood vessel formation
CN112543809A (zh) 包含C/EBPα saRNA的组合疗法
CN103145855B (zh) 基质金属蛋白酶抑制剂多肽及其应用
US9314497B2 (en) E2F as a target of hormone refractory prostate cancer
KR20200107842A (ko) 트레일 트라이머와 암표적 펩타이드를 멀티디스플레이하는 페리틴 나노케이지 및 이의 항암제로서의 용도
US20080096793A1 (en) Class III Slrp for the Treatment of Cancer
ITRM20000578A1 (it) Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patalogie associate ad una alterata attivazione
AU2006235742B2 (en) Conjugate comprising P21 protein for the treatment of cancer
KR20250075733A (ko) 심장 손상 후 심근세포를 보존 및 보호하고 심장 섬유증을 감소시키는 방법
US9605038B2 (en) Fusion peptide comprising dhFas-1 domain and MMP substrate and use thereof for preventing and treating rheumatoid arthritis

Legal Events

Date Code Title Description
FZDE Discontinued